- Home
- MRUS vs GKOS Comparison
MRUS vs GKOS Comparison
Compare MRUS & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- GKOS
- Stock Information
- Founded
- MRUS 2003
- GKOS 1998
- Country
- MRUS Netherlands
- GKOS United States
- Employees
- MRUS N/A
- GKOS N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- GKOS Medical/Dental Instruments
- Sector
- MRUS Health Care
- GKOS Health Care
- Exchange
- MRUS Nasdaq
- GKOS Nasdaq
- Market Cap
- MRUS 5.1B
- GKOS 5.4B
- IPO Year
- MRUS 2016
- GKOS 2015
- Fundamental
- Price
- MRUS $95.18
- GKOS $84.35
- Analyst Decision
- MRUS Buy
- GKOS Strong Buy
- Analyst Count
- MRUS 18
- GKOS 13
- Target Price
- MRUS $93.72
- GKOS $122.08
- AVG Volume (30 Days)
- MRUS 1.9M
- GKOS 1.6M
- Earning Date
- MRUS 10-31-2025
- GKOS 10-29-2025
- Dividend Yield
- MRUS N/A
- GKOS N/A
- EPS Growth
- MRUS N/A
- GKOS N/A
- EPS
- MRUS N/A
- GKOS N/A
- Revenue
- MRUS $56,606,000.00
- GKOS $469,820,000.00
- Revenue This Year
- MRUS $52.81
- GKOS $30.89
- Revenue Next Year
- MRUS N/A
- GKOS $24.36
- P/E Ratio
- MRUS N/A
- GKOS N/A
- Revenue Growth
- MRUS 57.54
- GKOS 30.38
- 52 Week Low
- MRUS $33.19
- GKOS $73.16
- 52 Week High
- MRUS $95.30
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- MRUS 78.45
- GKOS 52.08
- Support Level
- MRUS $94.75
- GKOS $83.46
- Resistance Level
- MRUS $95.10
- GKOS $102.80
- Average True Range (ATR)
- MRUS 0.34
- GKOS 5.56
- MACD
- MRUS -0.91
- GKOS 1.01
- Stochastic Oscillator
- MRUS 86.67
- GKOS 37.75
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.